Tag: Palforzia (AR101)
Nestlé to Acquire Aimmune Therapeutics
Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment.
Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...
Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued...
After 2 Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels.
Aimmune Warns Coronavirus Will Slow Marketing of Palforzia Treatment for Peanut...
The company warned that it has had to postpone in-person workshops to train physicians.
Aimmune Provides FDA Mandated Program for Patients Considering Treatment of Peanut...
The FDA seeks to mitigate risks associated with treatment by mandating a program that must be followed by patients, prescribers, pharmacies, and healthcare settings.
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development...
“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
What You Need to Know About the First Peanut Allergy Treatment...
Information for patients and their families about this new treatment option, what it means, and why it won’t be right for everyone.
FDA Approves Aimmune’s PALFORZIA as First Treatment for Peanut Allergy
Palforzia is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
